Cencora Elects Ellen Cooper to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026. Ms. Cooper is the Chairman, President and Chief Executive Officer of Lincoln Financial. Prior to assuming the role of CEO in May 2022, she served as Executive Vice President, Chief Investment Officer, Head of Enterprise Risk and Annuity Solutions. Prior to joining Lincoln, Ms. Cooper was with Goldman Sachs A.

Business Wire • 39 minutes ago

Cencora: High-Growth Specialty Services Firm Disguised As A Distributor

Cencora is transforming from a low-margin distributor to a higher-margin specialty services and oncology-focused business, underrecognized by the market. Cencora's acquisition of OneOncology is a transformational event, prompting raised long-term EPS growth guidance to 10-14% and signaling structurally higher margins. Recent results show robust U.S. segment performance, with Q4 operating income up 25.1%, and fiscal 2026 guidance projecting 8-10% operating income growth.

Seeking Alpha • Jan 21, 2026

Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 12, 2026

3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds

Cardinal Health, McKesson, and Cencora are showing how scale, specialty focus, and execution can drive market-beating returns despite macro pressure.

Zacks Investment Research • Jan 12, 2026

Here's Why You Should Retain Cencora Stock in Your Portfolio Now

Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.

Zacks Investment Research • Jan 8, 2026

Why Cencora (COR) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jan 8, 2026

Here's Why Cencora (COR) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jan 7, 2026

Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &.

Business Wire • Jan 6, 2026

These 3 Medical Stocks Have Wall Street's Bullish Vote for 2026

COR, ADUS and SEM earn bullish analyst support for 2026 as AI adoption, home care demand and facility expansion fuel medical sector growth.

Zacks Investment Research • Dec 24, 2025

4 Stocks Trading Near 52-Week High With More Upside Potential

Stocks like NVDA, RL, EXPE and COR are seeing price strength and have a high chance of carrying the momentum forward.

Zacks Investment Research • Dec 22, 2025